Cancer drug developer Affimed has filed for “insolvency,” warning investors Tuesday that there is “substantial doubt” the company can sustain itself. As a result of the filing, Affimed shares will be suspended from trading on the Nasdaq stock exchange beginning May 20. The company has been talking with “potential investors and partners” about deals or other ways in which it might raise capital, but has so far been unsuccessful. Affimed, which has three drugs in clinical testing, last reported cash holdings of 24 million euros as of Sept. 30, 2024.
https://finance.yahoo.com/news/bluebird-extends-deal-deadline-affimed-110000425.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.